Index -
P/E -
EPS (ttm) -
Insider Own 53.70%
Shs Outstand 31.85M
Perf Week -4.65%
Market Cap 718.22M
Forward P/E -
EPS next Y -
Insider Trans 98.80%
Shs Float 14.75M
Perf Month -
Income -
PEG -
EPS next Q -
Inst Own -
Short Float -
Perf Quarter -
Sales -
P/S -
EPS this Y -
Inst Trans -
Short Ratio -
Perf Half Y -
Book/sh -3.07
P/B -
EPS next Y -
ROA -
Short Interest -
Perf Year -
Cash/sh 1.74
P/C 13.00
EPS next 5Y -
ROE -
52W Range 20.29 - 26.08
Perf YTD -4.65%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -
52W High -13.54%
Beta -
Dividend TTM -
Quick Ratio 7.17
Sales past 5Y 0.00%
Gross Margin -
52W Low 11.16%
ATR (14) 2.78
Dividend Ex-Date -
Current Ratio 7.17
EPS Y/Y TTM -
Oper. Margin -
RSI (14) -
Volatility - -
Employees -
Debt/Eq 0.01
Sales Y/Y TTM -
Profit Margin -
Recom -
Target Price -
Option/Short No / Yes
LT Debt/Eq 0.00
EPS Q/Q -
Payout -
Rel Volume 0.89
Prev Close 21.23
Sales Surprise -
EPS Surprise -
Sales Q/Q -
Earnings -
Avg Volume 469.70K
Price 22.55
SMA20 3.41%
SMA50 3.41%
SMA200 3.41%
Trades
Volume 415,900
Change 6.22%
Sep-18-24 03:19AM
Sep-16-24 04:05PM
Sep-12-24 07:11PM
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Mathers Edward T Director Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:28 PM BASKETT FOREST 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:26 PM Behbahani Ali 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:24 PM Chang Carmen 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:23 PM Florence Anthony A. Jr. 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:21 PM Makhzoumi Mohamad 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:20 PM Walker Paul Edward 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:18 PM Yang Rick 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:17 PM SANDELL SCOTT D 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:14 PM ORBIMED ADVISORS LLC Director Sep 16 '24 Buy 16.00 750,000 12,000,000 3,158,428 Sep 17 08:13 PM New Enterprise Associates 17, 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:12 PM Frazier Life Sciences X, L.P. 10% Owner Sep 16 '24 Buy 16.00 625,000 10,000,000 4,552,774 Sep 17 08:11 PM Heron Patrick J Director Sep 16 '24 Buy 16.00 625,000 10,000,000 4,552,774 Sep 17 08:09 PM Aynechi Tiba Director Sep 16 '24 Buy 16.00 750,000 12,000,000 2,136,335 Sep 17 08:05 PM GORDON CARL L Director Sep 16 '24 Buy 16.00 750,000 12,000,000 3,158,428 Sep 17 08:05 PM
Index RUT
P/E -
EPS (ttm) -0.42
Insider Own 44.31%
Shs Outstand 138.14M
Perf Week 6.90%
Market Cap 739.05M
Forward P/E -
EPS next Y -0.43
Insider Trans 0.00%
Shs Float 91.67M
Perf Month 0.22%
Income -75.29M
PEG -
EPS next Q -0.11
Inst Own 51.05%
Short Float 10.27%
Perf Quarter 15.72%
Sales 0.00M
P/S -
EPS this Y -35.06%
Inst Trans 2.44%
Short Ratio 5.34
Perf Half Y -8.18%
Book/sh 0.74
P/B 6.10
EPS next Y 3.85%
ROA -58.02%
Short Interest 9.41M
Perf Year 19.10%
Cash/sh 0.74
P/C 6.08
EPS next 5Y -
ROE -79.48%
52W Range 3.12 - 5.70
Perf YTD -4.47%
Dividend Est. -
P/FCF -
EPS past 5Y 29.09%
ROI -58.72%
52W High -21.23%
Beta 0.96
Dividend TTM -
Quick Ratio 11.29
Sales past 5Y -20.00%
Gross Margin -
52W Low 44.14%
ATR (14) 0.22
Dividend Ex-Date -
Current Ratio 11.29
EPS Y/Y TTM -51.68%
Oper. Margin 0.00%
RSI (14) 54.27
Volatility 5.14% 4.97%
Employees 37
Debt/Eq 0.26
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 10.79
Option/Short Yes / Yes
LT Debt/Eq 0.26
EPS Q/Q -62.62%
Payout -
Rel Volume 2.92
Prev Close 4.64
Sales Surprise -
EPS Surprise -15.05%
Sales Q/Q -
Earnings Aug 12 AMC
Avg Volume 1.76M
Price 4.49
SMA20 3.27%
SMA50 1.89%
SMA200 -1.46%
Trades
Volume 5,149,833
Change -3.23%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-15-24 Initiated
JMP Securities
Mkt Outperform
$8
Nov-07-23 Initiated
Guggenheim
Buy
$7
May-16-23 Upgrade
Jefferies
Hold → Buy
$2 → $4
Mar-31-23 Downgrade
Jefferies
Buy → Hold
$2
Mar-16-21 Initiated
Piper Sandler
Overweight
$7
Mar-15-21 Initiated
Oppenheimer
Outperform
$4
Jun-13-19 Reiterated
H.C. Wainwright
Buy
$22 → $6
Jun-13-19 Downgrade
Ladenburg Thalmann
Buy → Neutral
$21 → $3
Jun-13-19 Downgrade
JMP Securities
Mkt Outperform → Mkt Perform
Aug-13-18 Resumed
ROTH Capital
Neutral
$12
Jan-03-18 Initiated
Ladenburg Thalmann
Buy
$35
Sep-27-17 Resumed
ROTH Capital
Buy
$40
Sep-22-17 Initiated
Jefferies
Buy
$20
Sep-11-17 Initiated
JMP Securities
Mkt Outperform
$20
Show Previous Ratings
Sep-08-24 06:45AM
Sep-06-24 04:05PM
Sep-03-24 04:05PM
Sep-01-24 10:26PM
Aug-29-24 08:41PM
04:05PM
Loading…
Aug-16-24 04:05PM
Aug-15-24 08:05AM
Aug-12-24 04:05PM
Jun-29-24 08:35PM
06:30PM
Jun-28-24 08:50AM
Jun-26-24 07:41AM
06:30AM
Jun-25-24 08:05PM
Jun-19-24 09:00AM
06:00AM
Loading…
Jun-11-24 06:00AM
May-29-24 08:05AM
May-21-24 08:20AM
May-19-24 12:15PM
May-16-24 04:05PM
May-09-24 10:55PM
04:05PM
May-07-24 04:05PM
(Business Wire) +6.26%
-5.13%
Apr-08-24 08:05AM
Mar-22-24 04:05PM
Mar-07-24 10:54PM
04:05PM
Mar-06-24 04:05PM
Feb-02-24 08:05AM
Jan-31-24 08:05AM
03:01PM
Loading…
Dec-30-23 03:01PM
Dec-21-23 08:05AM
Dec-20-23 08:05AM
Dec-15-23 04:05PM
Nov-21-23 08:05AM
Nov-09-23 04:05PM
Nov-08-23 04:05PM
Oct-06-23 04:05PM
Sep-27-23 07:29PM
Sep-17-23 10:54AM
Sep-12-23 09:12AM
Sep-05-23 04:05PM
Aug-10-23 04:05PM
Aug-04-23 04:05PM
Jul-13-23 07:00AM
Jun-26-23 04:05PM
08:05AM
Jun-02-23 08:05AM
May-28-23 08:26AM
May-16-23 12:32PM
May-15-23 08:05AM
May-05-23 04:05PM
Apr-03-23 07:33AM
Mar-31-23 04:05PM
Mar-30-23 04:05PM
Mar-20-23 06:35AM
Mar-17-23 06:47AM
Mar-16-23 06:51AM
Mar-15-23 06:44AM
Mar-13-23 06:32AM
Mar-10-23 07:04AM
Mar-09-23 06:33AM
Mar-08-23 06:30AM
Mar-07-23 06:34AM
Mar-06-23 04:05PM
07:22AM
Mar-03-23 06:38AM
Mar-02-23 06:44AM
Mar-01-23 06:01AM
Feb-28-23 04:05PM
06:43AM
Feb-27-23 06:50AM
Feb-23-23 07:21AM
Feb-22-23 06:56AM
Feb-21-23 07:35AM
Feb-17-23 06:27AM
Feb-16-23 07:28AM
Feb-15-23 07:01AM
06:24AM
Feb-14-23 08:05AM
06:23AM
Feb-13-23 07:30AM
Feb-10-23 06:42AM
Feb-09-23 06:51AM
Feb-08-23 06:45AM
Feb-07-23 06:46AM
Feb-06-23 06:56AM
Feb-03-23 06:32AM
Feb-02-23 06:43AM
Feb-01-23 06:14AM
Jan-31-23 06:50AM
Jan-30-23 06:42AM
Jan-27-23 03:47PM
07:00AM
Jan-26-23 06:44AM
Jan-25-23 06:39AM
Jan-24-23 06:48AM
Jan-23-23 06:58AM
Jan-20-23 08:05AM
06:55AM
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Pauls Matthew CHIEF EXECUTIVE OFFICER Dec 28 '23 Sale 4.71 84,000 395,900 1,302,674 Dec 29 04:35 PM Lowrance David L CHIEF FINANCIAL OFFICER Dec 28 '23 Sale 4.71 10,000 47,131 342,355 Dec 29 04:34 PM Elam Nevan C Director Dec 28 '23 Option Exercise 1.30 53,758 69,722 116,343 Dec 29 04:33 PM Elam Nevan C Director Dec 28 '23 Sale 4.71 93,843 442,291 22,500 Dec 29 04:33 PM Hawkins Richard J Director Dec 11 '23 Option Exercise 0.82 10,841 8,890 12,741 Dec 12 06:09 PM Elam Nevan C Director Dec 11 '23 Option Exercise 0.82 10,841 8,890 40,085 Dec 12 06:08 PM
Index RUT
P/E -
EPS (ttm) -1.54
Insider Own 23.78%
Shs Outstand 51.65M
Perf Week -23.10%
Market Cap 268.94M
Forward P/E -
EPS next Y -1.52
Insider Trans -1.62%
Shs Float 43.07M
Perf Month -27.11%
Income -80.55M
PEG -
EPS next Q -0.34
Inst Own 72.13%
Short Float 14.10%
Perf Quarter -1.65%
Sales 0.00M
P/S -
EPS this Y 25.68%
Inst Trans 0.09%
Short Ratio 9.43
Perf Half Y -12.01%
Book/sh 1.97
P/B 2.42
EPS next Y -8.89%
ROA -59.70%
Short Interest 6.07M
Perf Year 37.97%
Cash/sh 2.18
P/C 2.19
EPS next 5Y -
ROE -83.38%
52W Range 1.62 - 7.66
Perf YTD 69.40%
Dividend Est. -
P/FCF -
EPS past 5Y -49.79%
ROI -61.23%
52W High -37.86%
Beta 2.49
Dividend TTM -
Quick Ratio 6.87
Sales past 5Y 0.00%
Gross Margin -
52W Low 193.83%
ATR (14) 0.47
Dividend Ex-Date -
Current Ratio 6.87
EPS Y/Y TTM 32.20%
Oper. Margin 0.00%
RSI (14) 38.31
Volatility 10.54% 9.16%
Employees 54
Debt/Eq 0.21
Sales Y/Y TTM -
Profit Margin -
Recom 1.17
Target Price 13.83
Option/Short Yes / Yes
LT Debt/Eq 0.18
EPS Q/Q 31.17%
Payout -
Rel Volume 1.83
Prev Close 4.78
Sales Surprise -
EPS Surprise 6.95%
Sales Q/Q -
Earnings Aug 06 BMO
Avg Volume 643.56K
Price 4.76
SMA20 -17.94%
SMA50 -16.45%
SMA200 -0.15%
Trades
Volume 1,179,982
Change -0.42%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-31-24 Initiated
Raymond James
Outperform
$20
Jul-14-23 Initiated
Piper Sandler
Overweight
Jun-30-23 Upgrade
Stifel
Hold → Buy
$2 → $10
Jun-28-23 Upgrade
H.C. Wainwright
Neutral → Buy
$11
Jun-27-23 Upgrade
Wedbush
Neutral → Outperform
$10
Mar-29-22 Downgrade
Wedbush
Outperform → Neutral
Mar-22-22 Downgrade
H.C. Wainwright
Buy → Neutral
Sep-30-21 Initiated
Stifel
Hold
$10
Jan-07-21 Initiated
Wedbush
Outperform
$45
Nov-24-20 Initiated
Berenberg
Buy
$58
May-04-20 Initiated
H.C. Wainwright
Buy
$53
Feb-24-20 Initiated
JP Morgan
Overweight
$42
Feb-24-20 Initiated
Jefferies
Buy
Feb-24-20 Initiated
Cowen
Outperform
Feb-24-20 Initiated
Canaccord Genuity
Buy
$50
Show Previous Ratings
Sep-14-24 03:30AM
Aug-08-24 04:05PM
12:00PM
Aug-06-24 01:53PM
07:37AM
(Associated Press Finance)
07:30AM
Loading…
07:30AM
Jun-29-24 08:28PM
06:30PM
Jun-01-24 10:00AM
May-29-24 08:00AM
May-16-24 08:23AM
May-10-24 08:46AM
May-09-24 01:54PM
07:30AM
07:28AM
(Associated Press Finance)
08:50AM
Loading…
Apr-29-24 08:50AM
Apr-25-24 09:55AM
Apr-24-24 04:05PM
Apr-23-24 07:45AM
Apr-15-24 12:00PM
Apr-11-24 08:00AM
Apr-08-24 09:55AM
Apr-07-24 06:00PM
Apr-03-24 08:00AM
Mar-22-24 09:55AM
Mar-14-24 05:31AM
Mar-12-24 08:32AM
(Associated Press Finance) -5.50%
08:00AM
Mar-05-24 04:30PM
Feb-28-24 08:00AM
08:00AM
Loading…
Jan-04-24 08:00AM
Dec-13-23 07:00AM
Nov-07-23 08:00AM
Nov-06-23 08:07AM
07:48AM
(Associated Press Finance)
07:45AM
Oct-20-23 12:54PM
Oct-14-23 12:30PM
Oct-04-23 12:14PM
Sep-18-23 12:34PM
(American City Business Journals)
07:00AM
Sep-11-23 08:00AM
Sep-05-23 08:00AM
Aug-17-23 09:56AM
Aug-11-23 07:35AM
(Associated Press Finance)
07:30AM
Jul-25-23 07:43AM
Jul-16-23 10:05AM
Jun-29-23 08:57PM
05:48PM
Jun-28-23 04:23PM
07:15AM
Jun-27-23 07:00AM
Jun-13-23 08:00AM
Jun-02-23 08:00AM
May-18-23 10:17AM
May-09-23 07:46AM
07:30AM
Apr-18-23 08:00AM
Apr-17-23 04:01PM
Mar-09-23 07:52AM
07:30AM
Feb-27-23 08:00AM
Feb-15-23 05:46AM
Jan-19-23 05:41AM
Jan-05-23 08:00AM
Dec-19-22 08:00AM
Dec-12-22 08:00AM
Dec-09-22 09:35AM
09:04AM
Nov-09-22 08:00AM
Nov-08-22 08:00AM
Oct-26-22 08:00AM
Sep-06-22 08:00AM
Aug-28-22 09:41AM
Aug-09-22 08:00AM
Aug-03-22 08:00AM
Aug-01-22 08:55AM
Jul-02-22 08:29AM
Jun-06-22 08:00AM
Jun-01-22 07:00AM
May-17-22 07:00AM
May-12-22 04:30PM
May-11-22 04:30PM
Apr-28-22 12:52PM
(American City Business Journals)
Apr-25-22 09:00AM
Apr-18-22 07:00AM
Apr-07-22 04:30PM
07:00AM
Mar-17-22 05:00PM
Mar-02-22 08:00AM
Feb-22-22 08:00AM
Feb-16-22 05:28AM
Jan-11-22 07:00AM
Jan-10-22 07:00AM
Jan-05-22 08:00AM
Nov-18-21 05:27AM
Nov-08-21 04:05PM
07:45AM
Oct-08-21 04:05PM
Black Diamond Therapeutics, Inc. is a precision oncology medicine company, which engages in discovery and development of small molecule, masterkey therapies. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Versant Venture Capital VI, L. 10% Owner Aug 28 '24 Sale 6.32 221,600 1,400,556 3,726,341 Aug 30 04:16 PM David Epstein Former Employer Jul 31 '24 Proposed Sale 6.20 50,000 310,000 Jul 31 04:18 PM David Epstein Former Employee Jul 26 '24 Proposed Sale 6.20 50,000 310,000 Jul 26 05:54 PM BIOTECH GROWTH N V 10% Owner Oct 17 '23 Buy 2.34 400,000 934,080 8,517,839 Oct 19 03:08 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite